1. Antibodies
  2. Primary Antibodies
  3. Monoclonal Antibodies Recombinant Antibodies
  4. Prostatic Acid Phosphatase Antibody (YA1706)

Prostatic Acid Phosphatase Antibody (YA1706)

Cat. No.: HY-P81961
COA User Guide for Antibodies Technical Support

Prostatic Acid Phosphatase Antibody (YA1706) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Prostatic Acid Phosphatase.

For research use only. We do not sell to patients.

Size Price Stock Quantity
Free Sample   Apply now  
10 μL In-stock
50 μL In-stock
100 μL In-stock
250 μL   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • WB: Western Blot;
  • IHC-P: Immunohistochemistry-Paraffin;
  • IHC-F: Immunohistochemistry-Frozen;
  • ICC/IF: Immunocytochemistry/Immunofluorescence;
  • IF-Tissue: Immunofluorescence-Tissue;
  • mIHC: Multiplex Immunohistochemical;
  • IP: Immunoprecipitation;
  • ChIP: Chromatin Immunoprecipitation;
  • FC: Flow Cytometry;
  • ELISA: Enzyme Linked Immunosorbent Assay
  • Product Detail

  • Verification Image

  • Background

  • Documentation

Description

Prostatic Acid Phosphatase Antibody (YA1706) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Prostatic Acid Phosphatase.

Host

Rabbit

Clonality

Recombinant,Monoclonal

Molecular Weight
Predicted band size: 45 kDa;
Observed band size: 50 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
Species Reactivity
Human
SwissProt ID
Gene ID
Immunogen

A synthesized peptide derived from human PAP ( prostatic acid phosphatase) aa35-65.

Application &
Dilution Ratio
Application Dilution Ratio
WB
WB: Western Blot
1:500-1:1000
IHC-P
IHC-P: Immunohistochemistry-Paraffin
1:50-1:100
ICC/IF
ICC/IF: Immunocytochemistry/Immunofluorescence
1:50-1:200
IP
IP: Immunoprecipitation
1:50
Sensitivity Endogenous Purity Affinity Chromatography
Conjugation Non-conjugated Modification Unmodified
Isotype IgG  
Appearance

Liquid

Formulation

1.Supplied in rabbit IgG in phosphate buffered saline, pH 7.4, 150 mM NaCl, 0.02% sodium azide and 50% glycerol.
2.Supplied in 10 mM PBS, pH 7.4, 150 mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
Please refer to the lot-specific COA for specific buffer information.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Verification Image
ALL IHC-P mIHC ICC
  • Immunohistochemical analysis of paraffin-embedded human Prostate Cancer tissue using Prostatic Acid Phosphatase antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P81961,1:100 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.

  • Immunohistochemical analysis of paraffin-embedded human Prostate Cancer ‌ tissue using Prostatic Acid Phosphatase antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P81961,1:100 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.

  • Immunohistochemical analysis of paraffin-embedded human Prostate Cancer tissue using Prostatic Acid Phosphatase antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P81961,1:100 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.

  • Immunohistochemical analysis of paraffin-embedded human Prostate Cancer tissue using Prostatic Acid Phosphatase antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P81961,1:100 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.

  • Immunohistochemical analysis of paraffin-embedded human Esophageal Carcinoma tissue using Prostatic Acid Phosphatase antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P81961,1:100 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.

  • Immunohistochemical analysis of paraffin-embedded human Esophageal Carcinoma tissue using Prostatic Acid Phosphatase antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P81961,1:100 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.

  • Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human Prostate Cancer‌ tissue using Prostatic Acid Phosphatase antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P81961, 1:300 dilution) at room temperature for 60 minutes and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)(HY-D1832). The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium.

  • Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human Prostate Cancer tissue using Prostatic Acid Phosphatase antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P81961, 1:300 dilution) at room temperature for 60 minutes and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)(HY-D1832). The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium.

  • Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human Prostate Cancer‌ tissue using Prostatic Acid Phosphatase antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P81961, 1:300 dilution) at room temperature for 60 minutes and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)(HY-D1832). The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium.

  • Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human Esophageal Carcinoma tissue using Prostatic Acid Phosphatase antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P81961, 1:300 dilution) at room temperature for 60 minutes and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)(HY-D1832). The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium.

  • Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human Esophageal Carcinoma tissue using Prostatic Acid Phosphatase antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P81961, 1:300 dilution) at room temperature for 60 minutes and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)(HY-D1832). The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium.

  • Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human Esophageal Carcinoma tissue using Prostatic Acid Phosphatase antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P81961, 1:300 dilution) at room temperature for 60 minutes and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)(HY-D1832). The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium.

  • Immunocytochemistry analysis of PC-3 cells labeling Prostatic Acid Phosphatase with Prostatic Acid Phosphatase Antibody (HY-P81961) at 1/100 dilution . Cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 15 minutes at room temperature, then blocked with quick block buffer for 10 minutes at room temperature. Cells were then incubated with Prostatic Acid Phosphatase Antibody (HY-P81961) at 1/100 dilution in quick block buffer overnight at 4 ℃.AF488-conjugated Goat Anti-Rabbit IgG H&L(HY-P8002, Green) was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. The Nuclear counterstain was DAPI (Blue).

  • Immunocytochemistry analysis of PC-3 cells labeling Prostatic Acid Phosphatase with Prostatic Acid Phosphatase Antibody (HY-P81961) at 1/200 dilution . Cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 15 minutes at room temperature, then blocked with quick block buffer for 10 minutes at room temperature. Cells were then incubated with Prostatic Acid Phosphatase Antibody (HY-P81961) at 1/200 dilution in quick block buffer overnight at 4 ℃. AF488-conjugated Goat Anti-Rabbit IgG H&L(HY-P8002, Green) was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. The Nuclear counterstain was DAPI (Blue).

  • Immunocytochemistry analysis of PC-3 cells labeling Prostatic Acid Phosphatase with Prostatic Acid Phosphatase Antibody (HY-P81961) at 1/100 dilution . Cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 15 minutes at room temperature, then blocked with quick block buffer for 10 minutes at room temperature. Cells were then incubated with Prostatic Acid Phosphatase Antibody (HY-P81961) at 1/100 dilution in quick block buffer overnight at 4 ℃.AF488-conjugated Goat Anti-Rabbit IgG H&L(HY-P8002, Green) was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. The Nuclear counterstain was DAPI (Blue).

  • Immunocytochemistry analysis of PC-3 cells labeling Prostatic Acid Phosphatase with Prostatic Acid Phosphatase Antibody (HY-P81961) at 1/200 dilution . Cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 15 minutes at room temperature, then blocked with quick block buffer for 10 minutes at room temperature. Cells were then incubated with Prostatic Acid Phosphatase Antibody (HY-P81961) at 1/200 dilution in quick block buffer overnight at 4 ℃. AF488-conjugated Goat Anti-Rabbit IgG H&L(HY-P8002, Green) was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. The Nuclear counterstain was DAPI (Blue).

Background
Function:A non-specific tyrosine phosphatase that dephosphorylates a diverse number of substrates under acidic conditions (pH 4-6) including alkyl, aryl, and acyl orthophosphate monoesters and phosphorylated proteins (PubMed:10506173, PubMed:15280042, PubMed:20498373, PubMed:9584846). Has lipid phosphatase activity and inactivates lysophosphatidic acid in seminal plasma (PubMed:10506173, PubMed:15280042); Tyrosine phosphatase that acts as a tumor suppressor of prostate cancer through dephosphorylation of ERBB2 and deactivation of MAPK-mediated signaling (PubMed:20498373). In addition to its tyrosine phosphatase activity has ecto-5'-nucleotidase activity in dorsal root ganglion (DRG) neurons. Generates adenosine from AMP which acts as a pain suppressor (By similarity); (Microbial infection) Forms amyloid beta-sheet fibrils in semen. These fibrils, termed SEVI (semen-derived enhancer of viral infection) capture HIV virions, attach them to target cells and enhance infection (PubMed:18083097, PubMed:19451623, PubMed:19897482). SEVI amyloid fibrils are degraded by polyphenol epigallocatechin-3-gallate (EGCG), a constituent of green tea (PubMed:19451623). Target cell attachment and enhancement of HIV infection is inhibited by surfen (PubMed:19897482). Also similarly boosts XMRV (xenotropic murine leukemia virus-related virus) infection (PubMed:19403677)
Subcellular Localization:Secreted; Cell membrane; Single-pass type I membrane protein; Lysosome membrane; Single-pass type I membrane protein; Nucleus; Cytoplasm, cytosol
Expression:
Tissue_specificity:It is highly expressed in the prostate, limited to glandular and ductal epithelial cells. It is also expressed in the bladder, kidneys, pancreas, lungs, cervix, testes, and ovaries. It is weakly expressed in some pancreatic islet cells, squamous epithelium, pilosebaceous units, colonic neuroendocrine cells, and skin appendage structures. It is expressed at low levels in prostate cancer cells and tissues; it is also widely expressed. It is expressed in the sarcolemma of skeletal muscle.
Isoforms & Post-Translational Modification:P15309 has 3 isomers: P15309-1: 44566 Da (predicted); P15309-2: 48336 Da (predicted); P15309-3: 40443 Da (predicted).
N-glycosylated. High mannose content, partially sialylated and fucosylated biantennary complex. Also fucosylated with partially sialylated triantennary complex oligosaccharides;Proteolytically cleaved in seminal fluid to produce several peptides. Peptide PAPf39, the most prominent, forms amyloid beta-sheet fibrils, SEVI (semen-derived enhancer of viral infection)
Subunit:Homodimer; dimer formation is required for phosphatase activity
RRID
Database

Entrez Gene: 55 Human

SwissProt: P15309 Human

OMIM: 171790 Human

Research Field

Cell Biology

Synonyms
5' -NT; 5' -nucleotidase; ACP3; PAP; Prostatic acid phosphatase; TMPase
Documentation

Prostatic Acid Phosphatase Antibody (YA1706) Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Prostatic Acid Phosphatase Antibody (YA1706)
Cat. No.:
HY-P81961
Quantity:
MCE Japan Authorized Agent: